Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.27Sotac Pharmaceuticals demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a solid foundation and efficient use of capital. Growth prospects are promising, driven by revenue and operating profit increases. However, liquidity is a concern, with ratios suggesting potential difficulties in meeting short-term obligations. Efficiency metrics reveal challenges in asset utilization, particularly with fixed assets and capital turnover. Coverage ratios are also weak, primarily due to the absence of dividend coverage. While the company shows promise in certain areas, addressing liquidity and efficiency issues will be crucial for sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could further influence Sotac's financial trajectory.
Health Score : 5.27Sotac Pharmaceuticals demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a solid foundation and efficient use of capital. Growth prospects are promising, driven by revenue and operating profit increases. However, liquidity is a concern, with ratios suggesting potential difficulties in meeting short-term obligations. Efficiency metrics reveal challenges in asset utilization, particularly with fixed assets and capital turnover. Coverage ratios are also weak, primarily due to the absence of dividend coverage. While the company shows promise in certain areas, addressing liquidity and efficiency issues will be crucial for sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could further influence Sotac's financial trajectory.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
20.24
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
17.25
P/B RATIO
1.69
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.99
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
6.09
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹90.05 as on Sep 1, 2026.
Growth Score : 6.00Sotac Pharmaceuticals demonstrates promising growth, driven by revenue and operating profit increases. However, the negative EPS and net income growth rates raise concerns about the sustainability of this growth. The company shows good asset growth. Addressing the underlying factors affecting profitability is vital for ensuring long-term growth and financial stability. The pharmaceuticals industry's competitive landscape and regulatory changes may influence growth prospects.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | 68.97 | 35.06 | -6.73 | 4.12 |
| Operating Profit Growth Rate | -50 | 28.57 | 55.56 | 28.57 |
| Earnings Per Share (EPS) Growth | -2741.03 | 8.1 | 87.86 | -28.2 |
| Asset Growth Rate | 16.67 | 41.89 | 18.1 | 7.26 |
| Net Income Growth Rate | 100 | 125 | -33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 25.09 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 4 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 5 | Zenith Drugs Ltd | 4.63 | 7.41 | Neutral | 17.00 | 2.30 | 10.00 |
| 6 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 7 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. It focuses on a diverse range of therapeutic areas, positioning itself as a growing player in the Indian pharmaceutical sector with capabilities extending to finished formulations.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sotac Pharmaceuticals Ltd's P/E ratio (TTM) is 20.24, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sotac Pharmaceuticals Ltd's P/B ratio is 1.69, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sotac Pharmaceuticals Ltd's P/S ratio is 0.99, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sotac Pharmaceuticals Ltd's PEG ratio is 1.25.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sotac Pharmaceuticals Ltd's EV/EBITDA ratio is 6.09.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sotac Pharmaceuticals Ltd's ROE is 10.17%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sotac Pharmaceuticals Ltd's ROA is 13.53%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sotac Pharmaceuticals Ltd's ROCE is 13%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sotac Pharmaceuticals Ltd's operating margin is 17.82%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sotac Pharmaceuticals Ltd's net margin is 5.94%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sotac Pharmaceuticals Ltd's current ratio is 1.23.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sotac Pharmaceuticals Ltd's debt-to-equity ratio is 0.18.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sotac Pharmaceuticals Ltd's interest coverage ratio is 3.25.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sotac Pharmaceuticals Ltd's DPS is ₹0.21.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sotac Pharmaceuticals Ltd's EPS is -28.20.
(Source line: "Ratios as of 09 Nov 2026, based on last traded price of ₹90.05. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2018
Headquarters: Ahmedabad, Gujarat
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Intermediates, Finished Formulations, Contract Manufacturing
Stock Listing: NSE (SOTAC), BSE ({bse})
Promoter: Hareshbhai Vasudevbhai Patel and Chetankumar Kantibhai Patel / Sotac Promoter Group
Incorporated in 2018, Sotac Pharmaceuticals Ltd quickly established itself in the pharmaceutical sector. The company began commercial operations focusing on the manufacturing of APIs and intermediates. In 2023, it successfully migrated its listing from NSE Emerge to the mainboard of both NSE and BSE, marking a significant milestone in its growth trajectory.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | N/A | Operating Profit |
| Pharmaceutical Intermediates | N/A | Operating Profit |
| Finished Formulations | N/A | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Focuses on developing and manufacturing high-quality APIs for various therapeutic segments, serving both domestic and international markets.
Pharmaceutical Intermediates: Produces key chemical intermediates essential for the synthesis of APIs, ensuring backward integration and supply chain control.
Finished Formulations: Engaged in the manufacturing of various finished pharmaceutical dosage forms, catering to diverse healthcare needs.
Mr. Hareshbhai Vasudevbhai Patel - Chairman & Whole Time Director. He possesses over two decades of experience in the pharmaceutical industry, guiding the company's strategic vision. Mr. Chetankumar Kantibhai Patel - Managing Director. He brings extensive expertise in pharmaceutical operations and business development.
No major subsidiaries reported.
Migration from NSE Emerge to Mainboard (NSE & BSE) in 2023 following its IPO.
The Sotac Pharmaceuticals Ltd share price today is ₹90.05 on NSE (SOTAC), as of 10 Nov 2026.
As of 09 Nov 2026, Sotac Pharmaceuticals Ltd share price is ₹90.05, with previous close ₹90.05. Today's range is ₹90.05 to ₹90.05. The 52-week range is ₹86 to ₹132.95.
As of today, Sotac Pharmaceuticals Ltd's market cap is ₹99.96 crore (Small Cap).
Sotac Pharmaceuticals Ltd's current P/E ratio is 20.24, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 35.
Sotac Pharmaceuticals Ltd's current P/B ratio is 1.69.
Sotac Pharmaceuticals Ltd's current dividend yield is 0.23%. Last dividend of ₹0.00 per share was declared on N/A.
Sotac Pharmaceuticals Ltd's EPS (TTM) is ₹-28.20.
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. It focuses on a diverse range of therapeutic areas, positioning itself as a growing player in the Indian pharmaceutical sector with capabilities extending to finished formulations.
Sotac Pharmaceuticals Ltd is promoted by Hareshbhai Vasudevbhai Patel and Chetankumar Kantibhai Patel / Sotac Promoter Group, holding 72.85% as of 09 Nov 2026.
Sotac Pharmaceuticals Ltd is listed on NSE (SOTAC) and BSE ({bse}). Its next quarterly results are expected on Q2 FY25.
Cash Earnings Per Share (Cash EPS)